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Abstract  
 
Background: Data regarding both drug-related and non-drug-related costs in patients with 
Parkinson's disease (PD) are scarce, mainly due to the difficulties in data acquisition in 
experimental designs. Likewise, the reported impact of drug costs on total direct costs varies 
across different studies. In addition, the influence of comorbidities on both treatment costs 
and health-related quality of life has not been adequately evaluated.  
Methods: A sample of office-based neurologists (n=315) in Germany was asked to examine 
up to five consecutive patients with PD (n=1449) on a specified day during the study period. 
Patients of all ages were eligible and their evaluation was performed using standardized 
questionnaires.  
Results: PD-specific therapy costs increased with the stage of the disease, early onset of the 
disease and disease duration. The major costs were due to PD-related therapy, whereas other 
medications only resulted in minor costs. Disease stage mainly influenced direct therapy 
costs, with an observed increase of total daily costs from €7.3 to €11.3/day. In addition, 
disease onset at age <65 years resulted in total daily costs of €11.2 compared to late onset of 
disease (>75 years) with daily therapy costs of €5.3. In this patient group neuropsychiatric 
comorbidities such as dementia and depression were only insufficiently treated. In addition, 
these comorbidities severely affected health-related quality of life.  
Conclusion: Therapy costs were influenced by disease stage, disease onset as well as present 
comorbidities. Furthermore, comorbidities such as depression and dementia were diagnosed 
but were not adequately treated.   
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1. Introduction  
 
During the past century life expectancy has substantially increased in industrialized nations. 
While this is certainly gratifying, the ongoing aging of our society means that age-related 
diseases will have an increasing economic impact on national healthcare systems. This is 
especially true for chronic neurodegenerative disorders such as Parkinson's disease (PD). PD 
affects 1 to 2 out of 100 people aged 65 years and nearly 10% of people older than 80 years 
[1]. Recent projections suggest that the number of individuals with PD over the age of 50 will 
probably double by the year 2030 [2,39]. Moreover, the course of illness in PD can be 
aggravated by motor complications, such as motor fluctuations and dyskinesias, and by a 
number of non-motor complications, including psychiatric comorbidities, gastrointestinal 
symptoms and sleep disorders, which require additional demanding intervention strategies 
[3,4]. All of these complications can have a considerable impact on the economic burden of 
the disease, especially through the requirements of additional and complex therapeutic 
interventions (e.g., for motor complications and depression, and deep brain stimulation), 
additional in-patient stays (e.g., for patients suffering hallucinations) or premature nursing 
home placement (e.g., psychosis) [5].  
 
Although a number of studies have already evaluated the cost of illness in different countries 
[6], studies dealing with therapy costs in an office-based setting are relatively scarce and 
partly inconclusive [7]. Regarding the share of drug costs in the total cost, previous results 
from different studies varied from 20% in European investigations to up to more than 65% in 
a Chinese study [8]. Most reports suggest a strong association between the severity of PD and 
the expenses for disease-related medications, i.e., with disease progression, the drug costs 
increase by up to twice as much in advanced patients compared to patients in the early stages 
of the disease [9]. Similar associations have been found for motor complications, with their 
occurrence considerably increasing the cost of treating PD.  
 
Although PD patients frequently develop non-motor comorbidities, which influence quality of 
life [10], the economic impact of concomitant dementia and behavioral and psychological 
symptoms in PD outpatients has not been systematically investigated to date. This study, 
which was based on an epidemiological survey involving office-based neurologists, focuses 
on the daily costs of PD treatment and the economic burden as well as the impact of non-
motor complications such as dementia and depression.  
 
 
2. Methods  
 
2.1. Study design and recruitment procedure  
 
The study design and recruitment procedure of the German Study on the Epidemiology of 
Parkinson's Disease with Dementia (GEPAD) have previously been reported in detail [11,12]. 
Briefly, the primary goal of GEPAD was to estimate the prevalence of dementia and cognitive 
impairment among PD patients treated in the outpatient caresector. Data were derived from a 
random sample of PD outpatients (n=1449) who attended a representative sample of office-
based neurologists (n=315) in Germany on a specified day during the study period of 
September to October 2005. Patients of all ages and PD severity stages were eligible. Primary 
exclusion criteria were the patient's inability to read or write, severe cognitive impairment that 
precluded the application of the assessment or further logistical reasons preventing the 
examination (e.g., acute severe pain or medical emergencies).  
 
Eligible PD patients visited the respective neurologists (n=1749 in total) on the study day; 300 
patients were excluded from assessment by the physicians (89 for lack of consent, 39 for too 
severe impairment, 139 for logistical problems, and 33 for other reasons, for example 
language problems or sensory deficits). No clinical data were available for these patients. 
Thus, 1449 patients were included and examined according to the study protocol (overall 
participation rate: 82.3%). All patients included fulfilled the NINDS criteria for possible PD 
[13]. Moreover, n=873 of these patients also met the UK Brain Bank criteria for PD [14]. As 
previously reported by Riedel et al., the subgroups of patients did not differ in terms of age 
(p=0.140), gender distribution (p=0.196) or the primary study outcome variables, as described 
in the next section (i.e. frequency of dementia (p=0.761), MMSE score (p=0.409) or MADRS 
score (p=0.761)) [15]. Therefore, we included the entire sample in the analysis of this paper. 
All PD patients were rated in the “on” stage. The local ethics committee reviewed and 
approved the study protocol (EK No. 140082005). Written informed consent was obtained 
from all participating patients or their caregivers.  
 
2.2. Study material  
 
Each patient was evaluated by the neurologist with a questionnaire that consisted of three 
parts. Part A documented sociodemographic information. Part B was related to the 
documented PD status, including the Hoehn and Yahr Scale (HY) [16] and the Unified 
Parkinson's Disease Rating Scale (UPDRS) [17]. Furthermore, the presence of neurological, 
neuropsychiatric or somatic symptoms was recorded. Each physician was also asked to list 
their patients' current intake of PD-related drugs as well as any other medication. All agents 
were recorded in terms of daily dosage. Part C featured ratings of the cognitive level of 
functioning and depressive disorders. Cognitive impairment was assessed using the Mini-
Mental State Examination (MMSE) and was rated as “none” (scores of 25–30), “mild” (21–
24), “moderate” (11–20) or “severe” (0–10) [18]. The diagnosis of dementia was based upon 
the corresponding DSM-IV criteria, using a structured symptom list [19,20]. Depression was 
screened with the Montgomery-Asberg Depression Rating Scale (MADRS), using a cut-off 
score of ≥14 as an indicator of depressive symptoms [21]. Each patient was also administered 
the EQ-5D in order to assess their health-related quality of life [22].  
 
2.3. Drug cost calculation  
 
Daily therapy costs were calculated for each patient based on their documented medication. 
The dosage and dose per day were documented in the patients' questionnaire. Costs for 
prescription medications were obtained from the official German drug price list (“Rote Liste”, 
2006) and included a deduction according to the German social security code [23]. Only PD-
specific drugs and drugs used to treat PD complications were included in the calculation. The 
costs were calculated in Euros (€). The total costs (direct and indirect costs) were calculated 
from the statutory healthcare perspective.  
 
2.4. Statistical analyses  
 
Statistical analyses were performed using STATA Version 10.1 (StataCorp, 2008). The cost 
data are presented as median, arithmetic mean, standard deviation and 95% confidence 
intervals of the mean. The median cost can be interpreted as the typical cost per patient while 
the mean cost multiplied by the number of patients describes the total cost. Cost data are 
usually highly skewed and standard, nonparametric or normalizing methods are often not 
appropriate [24]. The bootstrap technique provides an appropriate and flexible approach for 
presenting and comparing skewed cost data. Bootstrap confidence intervals of 95% were 
calculated using the bias-corrected and accelerated percentile method [25]. The number of 
bootstrap replications B was 1000. Univariate comparisons of cost differences between 
groups were estimated using a linear regression approach with standard errors estimated by 
bootstrapping that was defined by potential cost predictors. The total scores of the EQ-5D 
were calculated using the scoring algorithm for the German population [26]. Differences in 
predictor variables for quality of life were estimated using a linear regression approach with 
standard errors estimated by bootstrapping.  
 
 
3. Results  
 
3.1. Characterization of the study sample  
 
Table 1 provides an overview of the study sample. The mean age of the study population was 
70.7±8.4 years and about a third of the patients were female. The mean disease duration was 
5.8±5.2 years and, on average, disease onset had occurred when patients were aged 64.8±9.7 
years. In 50% of all patients, the age of PD onset occurred before the age of 66, in 37.4% of 
patients between 66 and 75, and in 12.6% of patients after the age of 75 years. The majority of 
patients had been suffering from PD for up to 3 years (41.4%), and 4 to 6 years (22%). The 
disease duration for 36.6% of the patients had been longer than 7 years at the time of the 
study. The majority of patients were retired (88%, n=1250), in contrast to 5.5% who were still 
working; 13.1% claimed that retirement was due to PD and approximately 1% (n=11) of the 
patients were unemployed. Furthermore, 72.5% lived in a stable relationship while the 
remainder were single, widowed or divorced.  
 
3.2. Distribution of different PD medications within the study sample and the distribution of 
costs  
 
Table 2 shows the distribution of PD medications as stratified by the HY stage. It shows that 
75.8% of patients received levodopa. Another 13.6% were receiving levodopa and a COMT 
inhibitor, so that more than 90% of the patients received levodopa.  
 
Combined levodopa and COMT-inhibitor therapy was also frequently used and increased with 
advancing disease severity. Among the patients with severe cognitive impairment according 
to the MMSE (n=3), all patients received dopamine agonists and levodopa, two were treated 
with antidepressants, one patient was treated with amantadine and one patient received a 
neuroleptic drug.  
 
Overall, patients with dementia according to DSM-IV criteria received significantly less 
frequently dopamine agonists than non-demented patients (55% vs. 71%, p<.001, data not 
shown), whereas the slightly lower prescription rates in depressed vs. non-depressed patients 
according to the MADRS did not become significant (63.2% vs. 67.5%, p=.403).  
 
Three patients were subcutaneously treated with apomorphine. Two patients were rated as HY 
stage III and one was rated as stage IV. None suffered from dementia and all were 
experiencing motor fluctuations. Daily treatment costs for these patients amounted to a mean 
of €37.9. When calculating the drug costs for the entire group, these patients were excluded as 
they would have considerably distorted the data of the other patients.  
 
3.3. Treatment patterns and costs due to psychiatric complications  
 
The drug costs stratified by drug group, comorbidity and disease stage are compiled in Table 
3. The main costs were due to PDrelated drugs (~86%); only minor costs were contributed by 
antidementia drugs (4.6%), central nervous system (CNS) drugs (2.3%) or other medications 
(7.0%). Motor fluctuations, dyskinesias and advanced disease stage (HY stage/PD duration) 
significantly increased treatment costs. The presence of any of these led to a near doubling of 
both total and PD-associated daily costs. Young onset of disease was a cost-driving factor in 
this study, with significantly lower total costs occurring in patients with a disease onset after 
the age of 76 years (€5.3/day) in contrast to patients with a disease onset at <65 years (€11.2).  
 
Daily PD drug treatment costs decreased in patients with dementia or depression. Only 91 
patients (6.3%) received antidementia drugs, although 224 patients (15.5%) suffered from 
cognitive impairment according to the MMSE (≤24). The distribution of dementia drugs 
depending on the MMSE is shown in Table 3. The costs of antidementia drugs increased in 
univariate analyses according to age, disease stage and PD duration; however, the extent of 
cognitive impairment had a minor influence on costs. In the multivariate analyses, HY and PD 
duration were not significant predictors of costs, but age and cognitive impairment were.  
 
Further analyses of drug consumption showed that some drugs which lack current evidence of 
efficacy for cognition deficits, such as gingko biloba and other nootropics, were found to be 
used by 2% of the total number of patients. These costs totalled approximately €3.7/day 
(median value) per patient.  
 
Overall, 336 (25.2%) patients suffered from depression (MADRS≥14). However, only 154 
(44.6%) of these patients received antidepressant medication. The total costs were €3/patient 
per day. The presence of depression led to a considerable increase in treatment costs for CNS 
medication. The CNS costs increased in patients who showed motor fluctuations and 
dyskinesias. Therapy costs of CNS drugs also increased with the HY stage as well as with the 
presence of dementia. Nevertheless, the total costs of these drugs were low compared to PD 
drug costs.  
 
3.4. Treatment patterns and costs of other non-motor complications  
 
Gastrointestinal comorbidities were noted in 9.9% of the patients. Gastrointestinal 
medications such as antacids, antiemetics and macrogol (polyethylene glycol, used in chronic 
obstipation) were used by our patient sample. However, their use was infrequent and only 1% 
of the patients received these medications. Macrogol, in particular, was taken by patients of 
advanced age and with HY stage V. The use of antacids was negligible as the majority of 
patients were not taking any.  
 
Sleep disturbance was mentioned by 49% of the patients in our sample. However, drug 
consumption showed that only a minority of the patients received specific medication for this.  
 
3.5. Health-related quality of life in patients with PD  
 
The EQ-5D was analyzed based on HY stage, disease duration, motor fluctuations, 
dyskinesias and comorbidities (Table 4). The EQ-5D varied according to the HY stage, with a 
considerable reduction seen in the advanced stages of the disease. In patients with HY stage 
V, the utility value dropped to 0.33 (lower scores indicate poorer quality of life). Age, disease 
duration and the occurrence of motor complications decreased health-related quality of life 
(HrQoL).  
 
Comorbidities also influenced HrQoL. The patients who were suffering from cognitive 
impairment showed a decreasing utility value depending on whether the impairment was mild 
or moderate: patients with mild dementia did not experience much of a decrease in health-
related quality of life (0.61) compared to patients without this cognitive impairment (0.66). 
However, the progression of dementia to the moderate state led to a rapid decrease in the EQ-
5D to a value of 0.48.  
 
Moreover, anxiety, depression and hallucinations had a marked and significant influence on 
self-reported outcomes. An even greater effect on the EQ-5D values was seen when the 
presence of depression was further classified into mild, moderate or severe (data not shown). 
In the multivariate analyses with respect to psychiatric comorbidities, a major impact was 
found in patients suffering from depression, severe cognitive impairment and the occurrence 
of paranoid symptoms. The advent of hallucinations was not a predictive factor. Furthermore, 
gastrointestinal symptoms and advanced PD stage had a significant impact on HrQoL in PD 
patients.  
 
 
4. Discussion  
 
The present study is one of the first to evaluate treatment costs in a large and representative 
PD sample treated by office-based neurologists in Germany and taking non-motor symptoms 
and neuropsychiatric complications into account.  
 
4.1. Drug therapy and costs  
 
In the GEPAD study, therapy costs for PD increased from Hoehn and Yahr stages I to III, 
which reflects increasing disease complexity and demonstrates the need for combined therapy 
strategies in advanced stages of the disease, usually due to motor complications. Our data 
indicated a decrease in therapy costs in HY stages IV and V, as was also described by Dengler 
et al. [27]. According to Dengler, this change can be attributed to a switch in medication from 
expensive drugs in the early stages to levodopa in the later stages of the disease. In contrast, 
however, other studies described a continuing increase in therapy costs with advancing 
disease stage [28,29].  
 
The drug treatment of our older patients showed an inconsistent pattern regarding national 
recommendations [33]. More than 66% of all patients received dopamine agonists, which are 
actually indicated for patients younger than 70 years of age. However, only 48.6% of our 
patients belonged to this age group, therefore indicating a deviation from the 
recommendations for more than 17% of the patients. On the other hand, we observed an 
overall change in treatment strategy with increasing age in such a way that older patients were 
less likely to be treated with dopamine agonists, which is in agreement with the national 
recommendations.  
 
We observed that COMT inhibitors were frequently used by our patient sample, which also 
complies with national recommendations, since 34% of all patients suffered from motor 
fluctuations [33]. In a comparable publication by Möller et al., the percentage of patients who 
used COMT inhibitors was 20.4%, which is similar to the rate of use found in the present 
study [30].  
 
Although behavioral and psychological symptoms have been reported to frequently occur in 
PD patients and have a considerable impact on the well-being and quality of life of these 
patients, the prescription of drugs in our study did not reflect this. In our cohort, 28.1% 
suffered from dementia, 25.2% suffered from clinically relevant depression and 11.5% 
suffered from hallucinations. Antidepressants were prescribed in 20.2% of the patients. 
However, antidementia drugs were only prescribed in 6.3% and 1.5%, respectively, resulting 
in less than 7% of the total drug costs. This could partially reflect an often described difficulty 
in diagnosing depression in patients with PD as there is a substantial overlap between the 
symptoms of both disorders [34]. Therefore, it seems possible that depression might not be 
diagnosed on a regular basis in PD patients. This phenomenon was also described by Shulman 
et al. [35], who found that office neurologists failed to recognize the presence of depression 
and anxiety in 50% of the total cases. Interestingly, in our study, the diagnosis of depression 
was frequently made but treatment was not then initiated. However, we did not investigate the 
number of patients who were not diagnosed, and it is most likely that the number of 
depressive patients should have been higher, as seen in the study by Shulman et al. [35]. 
Another interpretation is that the clinician does not make a diagnosis of depression against a 
background of a severe underlying neurodegenerative disorder, despite increased MADRS 
scores. Furthermore, the provision of adequate therapy could be hampered by uncertainty over 
which drug to use as there are insufficient data regarding optimal antidepressive therapy. Only 
a few randomized controlled trials have tested the efficacy of antidepressants in patients with 
PD [36].  
 
Another common neuropsychiatric feature is the occurrence of dementia with increasing 
disease duration. For patients with PD, there is evidence to show the use of cholinesterase 
inhibitors for this indication, and rivastigmine is licensed in Germany [37]. German 
guidelines state that the effect is generally modest, but it is significant in 15% of all patients 
treated [33,38] and the treatment of patients with PD and mild to moderate dementia is 
recommended. However, there are side effects that need to be considered, such as a transient 
increase in tremor intensity during the initial dosing phase, as well as the common side effects 
of cholinesterase inhibitors. Our data showed that only 40% of the patients who suffered from 
moderate dementia received antidementia treatment. Further analyses are required in order to 
evaluate the prescription regime of patients with PD and dementia and to evaluate the reasons 
for the effects observed in our study.  
 
In summary, there is a major gap between current recommendations and the treatment 
patterns in ambulatory care concerning the adequate handling of neuropsychiatric 
complications in PD. Further studies are necessary in order to identify obstacles and provide 
adequate treatment of neuropsychiatric complications as these comorbidities – as already 
mentioned above – are major contributors to the quality of life of these patients.  
 
4.2. Health-related quality of life  
 
There is evidence to show that the choice of antiparkinsonian medication may affect HrQoL. 
In a recent article, 14 double-blind, placebo-controlled trials were assessed [31]. Several 
positive results for both COMT inhibitors and dopamine agonists were shown, but the results 
were ambiguous. A trial by Noyes compared the impact of pramipexole and levodopa on 
different domains of HrQoL. They showed that the dopamine agonist supported non-motor-
symptom-associated improvements, whereas levodopa improved HrQoL by a direct influence 
on motor symptoms. However, another study by Stocchi et al. examined the effect of 
levodopa with and without a COMT inhibitor with respect to the development of dyskinesias 
[32]. In a sample of more than 700 patients they found that combination therapy using COMT 
inhibitors did not delay the time of onset of dyskinesias compared to standard levodopa 
treatment. In contrast, combination therapy decreased the time to dyskinesias compared to 
levodopa treatment alone.  
 
Regarding neuropsychiatric comorbidities, we found a significant reduction in the HrQoL 
with increasing disease severity. The presence of dementia was both negatively correlated 
with, and influenced by, the presence of depression [31]. Therefore, adequate treatment is 
mandatory when patient-reported outcomes are important in the treatment of PD patients.  
 
4.3. Limitations  
 
This study has several limitations. Only office-based neurologists were included and thus the 
impact of patients treated in other levels of the healthcare system was neglected in this study. 
However, it was our primary aim to evaluate therapy costs in an office-based setting as this is 
how the majority of PD patients are treated in Germany. Asking neurologists to include 
patients in the study on a pre-specified day may have introduced the possibility of a bias. 
Therefore, the patient distribution must be interpreted with caution as this was not a 
community survey but a survey based on office-based neurologists. Furthermore, PD patients 
at earlier stages of the disease might initially be seen by their general practitioner rather than 
an office-based neurologist, thus their participation may have been underestimated in this 
study.  
 
Another important limitation refers to the calculation of therapy costs, which we restricted to 
the medications presented in this paper (i.e. anti-Parkinson medications and other CNS 
medications). We did not collect data on the costs of over-the-counter medications, which are 
also frequently used by PD patients. In addition, the cost estimates would have been higher if 
specialized PD centers and hospitals were included, since severe and difficult-to-treat cases 
are usually referred to these centers. It should also be noted that prior to the study assessment 
39 patients were excluded from the study by their physicians due to a degree of impairment 
that was too severe. Therefore, we lack further information regarding the clinical status and 
therapy expenses of these patients, whose higher level of comorbidity would have presumably 
resulted in higher costs compared to the patients who were included. Finally, although the 
patients were evaluated in the “on” state, we could not be sure that these patients were 
receiving the “best medical treatment”. This may have introduced a bias in the evaluation of 
patient-reported outcomes.  
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